drugset
drugset / Trial / NCT02273414

Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers

NCT02273414 ↗

Phase 1 Completed 35 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of the present study is to obtain information about the safety and tolerability of BIIL 284 BS after repeated dosing, to find the pharmacologically active dose range by determination of the surrogate marker CD 11b (= Mac-1) and to obtain preliminary pharmacokinetic data concerning steady state and accumulation factor

Timeline

Start
1999-07
Primary completion
1999-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AMELUBANT Small molecule 25 mg Oral
Subject AMELUBANT Small molecule 150 mg Oral
Subject AMELUBANT Small molecule 250 mg Oral

Indications

No indication recorded.